DCM
ESPR icon

Dupont Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Dupont Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,041
Closed -$143K – 652
2015
Q3 		$143K Hold
6,041
– – ﹤0.01% 581
2015
Q2 		$494K Hold
6,041
– – 0.01% 519
2015
Q1 		$559K Buy
+6,041
New +$390K 0.01% 499

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dupont Capital Management's ESPR Position: Q4 2015 in Review

Dupont Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2015, closing a stake of 6,041 shares — an estimated $143K sold.

Dupont Capital Management first reported a position in ESPR in Q1 2015 and held it in 3 quarters. The position peaked at $559K in Q1 2015. 113 funds tracked by Wall St. Rank hold ESPR as of Q4 2015.

  • Dupont Capital Management reported no remaining Esperion Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Dupont Capital Management sold 6,041 Esperion Therapeutics shares in Q4 2015, an estimated $143K.
  • Dupont Capital Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 3 quarters.
  • Dupont Capital Management's Esperion Therapeutics position peaked at $559K in Q1 2015.
  • 113 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2015.

Based on Dupont Capital Management's 13F filing for Q4 2015, filed 29 Jan 2016.